Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II–IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial-Reference-Cited by-同舟云学术

Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II–IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial

Published:2018-04 Issue:4 Volume:19 Page:461-473
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Tang Lin-Quan,Chen Dong-Ping,Guo Ling,Mo Hao-Yuan,Huang Ying,Guo Shan-Shan,Qi Bin,Tang Qing-Nan,Wang Pan,Li Xiao-Yun,Li Ji-Bin,Liu Qing,Gao Yuan-Hong,Xie Fang-Yun,Liu Li-Ting,Li Yang,Liu Sai-Lan,Xie Hao-Jun,Liang Yu-Jing,Sun Xue-Song,Yan Jin-Jie,Wu Yi-Shan,Luo Dong-Hua,Huang Pei-Yu,Xiang Yan-Qun,Sun Rui,Chen Ming-Yuan,Lv Xing,Wang Lin,Xia Wei-Xiong,Zhao Chong,Cao Ka-Jia,Qian Chao-Nan,Guo Xiang,Hong Ming-Huang,Nie Zhi-Qiang,Chen Qiu-Yan,Mai Hai-Qiang

Publisher

Elsevier BV

Subject

Oncology

Reference26 articles.

1. Is nasopharyngeal cancer really a “Cantonese cancer”?;Wee;Chin J Cancer,2010

2. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial;Chen;Lancet Oncol,2012

3. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis;Blanchard;Lancet Oncol,2015

4. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial;Chen;J Natl Cancer Inst,2011

5. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial;Chitapanarux;Eur J Cancer,2007

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing efficacy and reducing toxicity: Therapeutic optimization in locoregionally advanced nasopharyngeal carcinoma;Cell Reports Medicine;2024-06

2. The Application of Emodin Treatment on Nasopharyngeal Carcinoma Therapy;Biomedicines;2024-02-21

3. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with chemoradiotherapy for induction chemotherapy resistant locally advanced nasopharyngeal carcinoma: A prospective phase II study;Translational Oncology;2024-01

4. Eosinophil dynamics during chemo-radiotherapy correlate to clinical outcome in stage Ⅱ-Ⅳa nasopharyngeal carcinoma patients: Results from a large cohort study;Radiotherapy and Oncology;2023-11

5. Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial;European Journal of Cancer;2023-11